Table of Contents
Hepatitis is a serious liver disease caused by various hepatitis viruses, including hepatitis B and hepatitis C. The development of effective antiviral drugs has significantly improved the management and prognosis of these infections. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several key antiviral medications over the years. This article reviews some of the most important hepatitis antiviral drugs approved for clinical use.
Hepatitis B Antiviral Drugs
Hepatitis B virus (HBV) infection can become chronic, leading to cirrhosis and liver cancer. Several antiviral drugs have been approved to suppress HBV replication and prevent disease progression.
Tenofovir Disoproxil Fumarate (TDF)
Approved by the FDA in 2008, tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NRTI) that effectively suppresses HBV DNA levels. It is also used in HIV treatment. Its high barrier to resistance makes it a preferred choice for long-term therapy.
Entecavir
Entecavir received FDA approval in 2005. It is a potent NRTI with a high genetic barrier, reducing the risk of resistance. It is widely used for treating chronic hepatitis B and has shown excellent efficacy in suppressing viral replication.
Hepatitis C Antiviral Drugs
Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma. The advent of direct-acting antivirals (DAAs) has revolutionized treatment, offering high cure rates with shorter therapy durations.
Sofosbuvir
Approved by the FDA in 2013, sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. It forms the backbone of many combination therapies, providing cure rates exceeding 90% in many patient populations.
Ledipasvir/Sofosbuvir (Harvoni)
Approved in 2014, this fixed-dose combination targets multiple steps in the HCV lifecycle. It is highly effective across different genotypes and has simplified HCV treatment regimens.
Emerging and Next-Generation Antivirals
Research continues to develop new agents with improved efficacy, safety, and resistance profiles. Several drugs are in clinical trials, including pan-genotypic agents and those targeting viral entry or replication mechanisms.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Approved in 2017, Vosevi is a combination therapy effective for patients who failed previous treatments. It offers a broad activity against multiple genotypes of HCV.
Conclusion
The approval of these antiviral drugs has transformed the landscape of hepatitis management. Continuous research and development are essential to address remaining challenges, including drug resistance and treatment accessibility. Healthcare providers should stay informed about the latest approvals and guidelines to optimize patient outcomes.